{
    "Trade/Device Name(s)": [
        "DRI Cocaine Metabolite Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K181499",
    "Predicate Device Reference 510(k) Number(s)": [
        "K960187"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "July 6, 2018",
    "Summary Letter Received Date": "June 7, 2018",
    "Submission Date": "June 5, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU680 clinical analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Enzyme-labeled antibody competitive binding assay",
        "Spectrophotometry"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Cocaine Metabolite Assay, an enzyme immunoassay for qualitative and semi-quantitative detection of benzoylecgonine in urine.",
    "Indications for Use Summary": "For qualitative and/or semi-quantitative determination of benzoylecgonine (cocaine metabolite) in human urine at cutoff concentrations of 150 ng/mL or 300 ng/mL; results are for preliminary screening and require confirmation by more specific methods such as LC-MS/MS.",
    "fda_folder": "Toxicology"
}